Bradley JS, Antadze T, Ninov B, et al. - In 2014, tedizolid phosphate was approved for treatment of adults with acute bacterial skin and skin structure infections (ABSSSIs). Researchers conducted this randomized, assessor-blind, global phase 3 study comparing tedizolid (administered as tedizolid phosphate) vs active comparators for the treatment of Gram-positive ABSSSIs in adolescents (12 to < 18 years of age). Of 121 enrolled participants, 120 received treatment (tedizolid, n = 91; comparator, n = 29); active comparator was selected by investigator from an allowed list per local standard of care. Safety and efficacy of tedizolid was identified to be similar to comparators for the treatment of ABSSSIs in adolescents.